1 most recent filing and news item mentioning BMS. Updated every 60 seconds.
Earnings|GuidanceJul 30, 2026Positive
Bristol Myers reported Q2 2026 revenues of $13.0B and lifted its full-year outlook, highlighting strong growth from its portfolio of oncology, hematology, and cardiovascular medicines.
View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.